Updated:
Form Life
FORM Life funds and incubates companies leveraging cutting-edge science and technology to revolutionize healthcare.
Form Life
FORM Life funds and incubates companies leveraging cutting-edge science and technology to revolutionize healthcare.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Principals
Markus Okumus
Founding Partner
Tony Wyss-Coray
Scientific Founder
Vahik Soghom
Associate/IR
Sector focus
Frequently asked questions
Who runs investment decisions at Form Life?
Founding Partner Markus Okumus leads investment decisions, supported by Scientific Founder Tony Wyss-Coray. The firm lists Vahik Soghom as an Associate/IR, handling investor relations. No investment committee structure or advisory board has been publicly disclosed.
How does Form Life source proprietary deal flow?
The firm's primary sourcing edge comes from Prof. Tony Wyss-Coray's Stanford neuroscience lab and its extended academic network. This connection provides early visibility into translational research in aging, immunology, and data-driven diagnostics. Form Life's stated focus on 'hard-nosed science' suggests it underwrites opportunities that emerge directly from validated scientific findings rather than conventional venture networks.
Is Form Life structured as a single family office or a traditional venture firm?
Form Life operates as a private equity firm targeting early-stage healthcare — not a family office. Its small team and dual-operator structure (firm-builder plus scientific founder) give it some characteristics of a specialized incubator, but its formal designation and investment activity place it squarely in the venture capital category.
Does Form Life participate in fund commitments or only direct deals?
Based on its disclosed portfolio of five named direct investments — including Vero Bioscience, People Science, RxDiet, and Teal Rise — Form Life appears to execute only direct seed and startup-stage deals. There is no evidence it commits capital to external venture funds.
What investment stages does Form Life typically target?
Form Life focuses on the earliest stages: seed and startup. Its portfolio composition — companies still building core science and initial product-market fit — confirms a pre-Series A mandate. The firm does not list any growth-stage or late-stage holdings.
How is the scientific-founder role structurally embedded at Form Life?
Prof. Tony Wyss-Coray holds the title of Scientific Founder, not merely Scientific Advisor. This suggests he is a founding equity partner and likely involved in deal evaluation and portfolio support. His concurrent role at Stanford implies Form Life operates with a model where academic affiliation flows directly into investment activity, a structure common among deeply technical healthcare funds.
Does Form Life maintain philanthropic structures, and how are they separated?
No philanthropic foundation, donor-advised fund, or impact-investing vehicle has been publicly linked to Form Life. The firm's investments are structured as standard venture deals, not mission-related or program-related investments.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: